Understand the molecular epidemiology and drug-resistance mechanisms of key microbial pathogens as a foundation for improved diagnosis, treatment, and control of infectious diseases in a Global Health context, with emphasis on vulnerable populations.
2.Identify critical microbial lineages and resistance mechanisms that impact disease transmission and therapeutic outcomes;
3.Support the development of innovative antimicrobial strategies and evaluate their potential for clinical and public health use;
4.Enhance early detection and monitoring systems for infection and resistance, strengthening surveillance capacity;
5. Investigate microbial evolution and genetic adaptation to inform targeted intervention strategies;
6. Contribute to locally adapted infection control measures and capacity-building initiatives.
PRIME will introduce new research tools (especially AI-driven resistance prediction for new & repurposed drug development) and themes. Research will explore the relationship between efflux activity, virulence traits, and biofilm formation, generating novel insights into microbial pathogenesis and resistance.
The Galleria mellonella invertebrate infection model will be further developed, in combination with chemogenomic approaches, to advance microbial pathogenicity studies, drug efficacy screening, and host pathogen interaction analyses.
PRIME will expand metavirome and metagenome analyses of wastewater and cohort-related samples using whole-genome sequencing (WGS), phylogenetic and phylodynamic tools.
PRIME is a core member of international collaborative networks on AMR (eg. EUResist & EUCAST Myco), TB research (eg. ESGMYC), and genomic epidemiology of viruses (eg.ESAR), engaging with both academic consortia and public–private partnerships. These efforts aim to enhance infectious disease surveillance and pandemic preparedness, providing actionable insights into emerging microbial threats within a global health framework.
Recent Highlights
EDCTP Forum 2027: Abstract Submissions Open Until 2 September
Submit your research and join global health leaders in Madrid in 2027 to share innovations, insights and impact in health research.
Read More
GHTM | IHMT NOVA represented in the COST Action 1HEALTH-NET Management Committee
GHTM joins a new European One Health network to advance infectious disease detection, surveillance and prevention across Europe.
Read More
GHTM researcher Ana Armada appointed to the Management Committee of COST Action – ONE-LEP
Ana Armada joins the ONE-LEP Management Committee, strengthening Portugal’s role in One Health research on leptospirosis and rodent-borne diseases.
Read More
ANTENNA Project Launched to Strengthen Training and Research Capacity in Africa
ANTENNA launches to strengthen epidemiology, statistics, research and data analysis capacity across Eastern, Central and Western Africa.
Read More
The TEAM
